Oddo BHF - BioNTech SE (BNTX) BioNTech SE : RD Day tourné vers l’oncologie

Report

Oddo BHF

Damien Choplain ...

Martial Descoutures

BioNTech SE : R&D Day tourné vers l’oncologie

>Trois approches complémentaires pour 5 actifs flagships - Lors du R&D day qui s’est tenu hier, BioNTech a fait un focus sur son portefeuille en oncologie structuré autour de trois approches complémentaires et potentiellement synergiques : immunomodulateurs, vaccins à ARNm et thérapie ciblée. Coté produits, la société a mis en avant 5 molécules flagships : 1/ BNT327 (bispécifique PDL1x VEGF), 2/ BNT122 autogene cevumeran (Vaccin à ARNm personnalisé), 3/ FixVac (Vacc...

15/11/2024 1 FR

Underlying

BioNTech SE

See profile

US09075V1026 NASDAQ Stock Market Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Damien Choplain

Martial Descoutures

Other Reports on these Companies

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/11/2024

...

4h / 55m 4h / 55m 1 FR

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024

Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...

5h / 11m 5h / 11m 1 EN

Oddo BHF

BioNTech SE : R&D Day focused on oncology

>Three complementary approaches for five flagship molecules - - At yesterday's R&D day, BioNTech focused on its oncology portfolio structured around three complementary and potentially synergistic approaches: immunomodulators, mRNA vaccines and targeted therapy. On the product side, the company highlighted five flagship molecules: 1/ BNT327 (PDL1x VEGF bispecific), 2/ BNT122 autogenous cevumeran (individualised mRNA vaccine), 3/ FixVac (Off-the-shelf mRNA vaccin...

6h / 20m 6h / 20m 1 EN

Lectra : Feedback meeting analystes : faible visibilité sur les commandes mais le CA récurrent/Saas et la rentabilité devraient continuer de progresser

>Prudence toujours de mise à court terme sur les commandes mais le tableau n’est pas aussi noir que possiblement craint avant la publication T3 - Au regard des publications récentes sur les deux principaux marchés finaux de Lectra (mode et automobile), le marché anticipait probablement une détérioration plus forte sur les commandes. Dans les faits, le T3 2024 n’est pas bon mais pas catastrophique pour autant (niveau flat y-o-y) et nous interprétons un message plutôt ...

1h / 30m 1h / 30m 1 FR

Louis Boujard ... (+3)

Louis Boujard
CFA
Philippe Ourpatian

E.ON : Publication sans surprise mais des signes encourageants pointent à l’horizon

>Peu de risques et 2 catalyseurs en vue - Les perspectives d’E.ON nous semble encourageantes. Compte tenu de la performance enregistrée sur 9M et malgré des effets de base difficiles, il semble acquis que le groupe sera en mesure d’atteindre ses objectifs annuels cette année ce qui éloigne les risques à court terme. Mais plus important, les développements attendus sur les prochains trimestres pourraient permettre d’augmenter le potentiel de revalorisation au-dessus de...

1h / 36m 1h / 36m 1 FR

Louis Boujard ... (+3)

Louis Boujard
CFA
Philippe Ourpatian

E.ON : 9M 2024 publication had no surprises but encouraging signs taking shape

>Few risks and two catalysts in line of sight - E.ON’s prospects look encouraging, in our view. Given the performance achieved over 9M 2024 and despite challenging comps, it seems certain that the group will be able to hit its annual targets year, which removes risks in the short term. But more importantly, the developments expected over the next few quarters could increase the stock’s re-rating potential above current market expectations with two potential catalysts ...

1h / 36m 1h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BioNTech SE : R&D Day tourné vers l’oncologie

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/11/2024

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024

BioNTech SE : R&D Day focused on oncology

Lectra : Feedback meeting analystes : faible visibilité sur les commandes mais le CA récurrent/Saas et la rentabilité devraient continuer de progresser

E.ON : Publication sans surprise mais des signes encourageants pointent à l’horizon

E.ON : 9M 2024 publication had no surprises but encouraging signs taking shape

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe